Corbus Pharmaceuticals Holdings (LTS:0SZI) Change In Payables And Accrued Expense : $3.68 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Change In Payables And Accrued Expense?

Corbus Pharmaceuticals Holdings's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-2.76 Mil. It means Corbus Pharmaceuticals Holdings's Accounts Payable & Accrued Expense declined by $2.76 Mil from Dec. 2023 to Mar. 2024 .

Corbus Pharmaceuticals Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $6.06 Mil. It means Corbus Pharmaceuticals Holdings's Accounts Payable & Accrued Expense increased by $6.06 Mil from Dec. 2022 to Dec. 2023 .

Corbus Pharmaceuticals Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Change In Payables And Accrued Expense Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

16.92

-3.87

-17.87

-4.35

6.06

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.38	0.14	4.32	1.99	-2.76

Corbus Pharmaceuticals Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.68 Mil.

Corbus Pharmaceuticals Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

CRBP:USA

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Headlines

No Headlines